Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update NeuroBo Becomes MetaVia On November 18, 2024, NeuroBo Pharmaceuticals ...

As anti-obesity medications gain popularity, a new concern has also gained traction among researchers: increased food waste. A self-administered online survey sponsored by Ohio State found that 25% of ...

Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

While surgery has a low risk for complications, when they do occur, they are serious. This may explain why only 5%-10% of ...

Medically reviewed by Peter Weiss, MD Ozempic is the brand name of a medication called semaglutide, a glucagon-like peptide-1 ...

The medications − part of a class of drugs called GLP-1, or glucagon-like peptide-1, receptor agonists − were first used to treat diabetes but have since been approved for obesity, which has ...

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets ...